Advise women of childbearing potential of possible risks. Contraindicated in patients with a history of hypersensitivity to oprelvekin or any component. Use appropriate precautions in case allergic reactions occur. Presence of antibodies or injection site reactions not correlated with clinical symptoms such as anaphylactoid reactions or a loss of clinical response to drug. No anaphylactoid or other severe adverse allergic reactions were reported in clinical studies following single or repeated doses of drug.
Fluid retention is reversible within several days following discontinuation.
Consider drainage if indicated. Capillary leak syndrome not seen. Use caution in patients who may develop fluid retention from associated medical conditions or whose medical condition may be worsened by fluid retention. Changes predominantly are due to increase in plasma volume primarily related to renal sodium and water retention. Decrease in hemoglobin concentration typically starts within 3-5 days of therapy and is reversible over about a week after drug is discontinued.